Mitsuru Ando
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mitsuru Ando has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Yuki Takahashi
Department of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshidashimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan
13 shared publications - Yoshinobu Takakura
Department of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshidashimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan
11 shared publications Makiya Nishikawa
Department of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan
8 shared publicationsYoshihiko Watanabe
Department of Biopharmaceutics and Drug Metabolism and ‡Department of Molecular Microbiology, Graduate School of Pharmaceutical Science, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan
7 shared publications- Makiya Nishikawa
Faculty of Pharmaceutical Sciences, Tokyo University of Science
5 shared publications - Kazunari Akiyoshi
Department of Immunology, Graduate School of Medicine
4 shared publications
Latest Publications
- Open Access
- 20 July 2026
- Published by Elsevier in Materials & Design
- Vol. 268
Mesenchymal stem cell membrane coating of gelatin nanospheres with drug release ability for inflammatory tissue targeting
- 20 July 2026
- Published by Elsevier in Materials & Design
- Vol. 268
Open AccessMesenchymal stem cell membrane coating of gelatin nanospheres with drug release ability for inflammatory tissue targeting
- Open Access
- 15 July 2026
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
Suppressive Immune Response of Poly(sarcosine) Conjugated Proteins: PSARylation.
Polymer conjugation is a widely used strategy to improve the pharmacokinetics of protein therapeutics by extending their half-life and protecting them from degradation. Poly(ethylene glycol) (PEG) is the most commonly used polymer for this purpose. However, its use can trigger unwanted immune responses, leading to the production of anti-PEG antibodies that compromise efficacy. This issue has driven the search for alternative polymers, with poly(sarcosine) (PSAR), derived from an endogenous amino acid, emerging as a promising candidate. Despite this potential, the immunogenicity of PSAR-protein conjugates (PSARylation) has not been systematically compared with that of PEGylated counterparts. In this report, we show that conjugating a model protein antigen to high-molecular-weight PSAR more effectively suppresses immune responses against both the protein and the polymer than PEG. Although polymer conjugation has traditionally been viewed as a means of steric "masking" of a protein, our results demonstrate that the chemical nature of the polymer is a critical, independent factor, as PSAR conjugates elicited lower antibody production than PEG conjugates of identical hydrodynamic size. This study highlights polymer selection as an important design parameter for minimizing immunogenicity in next-generation protein therapeutics. Polymers derived from biological building blocks, such as PSAR, offer a promising route to developing safer, more effective biopharmaceuticals with better tolerance and reduced risk of adverse immune reactions.
- 15 July 2026
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
Open AccessSuppressive Immune Response of Poly(sarcosine) Conjugated Proteins: PSARylation.
Polymer conjugation is a widely used strategy to improve the pharmacokinetics of protein therapeutics by extending their half-life and protecting them from degradation. Poly(ethylene glycol) (PEG) is the most commonly used polymer for this purpose. However, its use can trigger unwanted immune responses, leading to the production of anti-PEG antibodies that compromise efficacy. This issue has driven the search for alternative polymers, with poly(sarcosine) (PSAR), derived from an endogenous amino acid, emerging as a promising candidate. Despite this potential, the immunogenicity of PSAR-protein conjugates (PSARylation) has not been systematically compared with that of PEGylated counterparts. In this report, we show that conjugating a model protein antigen to high-molecular-weight PSAR more effectively suppresses immune responses against both the protein and the polymer than PEG. Although polymer conjugation has traditionally been viewed as a means of steric "masking" of a protein, our results demonstrate that the chemical nature of the polymer is a critical, independent factor, as PSAR conjugates elicited lower antibody production than PEG conjugates of identical hydrodynamic size. This study highlights polymer selection as an important design parameter for minimizing immunogenicity in next-generation protein therapeutics. Polymers derived from biological building blocks, such as PSAR, offer a promising route to developing safer, more effective biopharmaceuticals with better tolerance and reduced risk of adverse immune reactions.
- 11 February 2026
- Published by Wiley in Macromolecular Rapid Communications
- Vol. 47 (10) , e00826
Preparation of Platelet Membrane‐Coated Gelatin Nanoparticle Toward Alternative to Platelet Preparation
Platelets play a critical role in hemostasis and tissue repair; however, their short shelf life of approximately four days poses a major challenge to their supply. This limitation underscores the need for long‐term storage alternatives. In this study, we developed and characterized platelet membrane–coated gelatin nanoparticles (PL‐GNPs) as potential platelet substitutes. PL‐GNPs were prepared by coating gelatin nanoparticles (GNPs) with platelet‐derived membrane vesicles. Cryo‐electron microscopy revealed the formation of a core–shell structure, and immunoblotting demonstrated that key platelet surface proteins, CD41 and CD61, were preserved on the PL‐GNP surface in the same orientation as in platelets. The membrane coating improved the stability of the nanoparticles against collagenase‐dependent degradation. Moreover, PL‐GNPs bound effectively to fibrinogen, an essential interaction in thrombus formation, and retained this function even after one month of storage at 4°C. Collectively, these findings indicate that PL‐GNPs recapitulate the critical structural and functional properties of native platelets and hold promise as a stable, long‐term storable alternative to conventional platelet preparations for therapeutic use.
- 11 February 2026
- Published by Wiley in Macromolecular Rapid Communications
- Vol. 47 (10) , e00826
Preparation of Platelet Membrane‐Coated Gelatin Nanoparticle Toward Alternative to Platelet Preparation
Platelets play a critical role in hemostasis and tissue repair; however, their short shelf life of approximately four days poses a major challenge to their supply. This limitation underscores the need for long‐term storage alternatives. In this study, we developed and characterized platelet membrane–coated gelatin nanoparticles (PL‐GNPs) as potential platelet substitutes. PL‐GNPs were prepared by coating gelatin nanoparticles (GNPs) with platelet‐derived membrane vesicles. Cryo‐electron microscopy revealed the formation of a core–shell structure, and immunoblotting demonstrated that key platelet surface proteins, CD41 and CD61, were preserved on the PL‐GNP surface in the same orientation as in platelets. The membrane coating improved the stability of the nanoparticles against collagenase‐dependent degradation. Moreover, PL‐GNPs bound effectively to fibrinogen, an essential interaction in thrombus formation, and retained this function even after one month of storage at 4°C. Collectively, these findings indicate that PL‐GNPs recapitulate the critical structural and functional properties of native platelets and hold promise as a stable, long‐term storable alternative to conventional platelet preparations for therapeutic use.
- 19 November 2025
- Published by Wiley in Macromolecular Rapid Communications
- Vol. 47 (10) , e00702
Poly(2‐Propyl‐2‐Oxazoline)‐Induced Lipid Nanotube Formation in Phospholipid Multilayers
Synthetic amphiphilic polymers are promising regulators of biomembrane morphology because of their moderate hydrophobicity and tunable molecular properties, including higher‐order structure, charge, topology, and stimuli responsiveness. However, few studies have demonstrated the direct morphological control of membranes using such polymers, and systematic molecular design strategies remain underdeveloped. In this study, we report that poly(2‐propyl‐2‐oxazoline) (PPOx), a representative amphiphilic polymer, induces the formation of long string‐like structures from multilayered phospholipid films coated on silica particles. Cryo‐electron microscopy suggests that these structures are hollow lipid nanotubes, and fluorescence recovery after photobleaching (FRAP) confirmed the lateral mobility of lipids within the membranes. Furthermore, we developed an image analysis pipeline to quantitatively assess nanotube formation and evaluated the tube‐inducing efficiency of a series of poly(2‐alkyl‐2‐oxazoline) homopolymers with varying side‐chain hydrophobicities.
- 19 November 2025
- Published by Wiley in Macromolecular Rapid Communications
- Vol. 47 (10) , e00702
Poly(2‐Propyl‐2‐Oxazoline)‐Induced Lipid Nanotube Formation in Phospholipid Multilayers
Synthetic amphiphilic polymers are promising regulators of biomembrane morphology because of their moderate hydrophobicity and tunable molecular properties, including higher‐order structure, charge, topology, and stimuli responsiveness. However, few studies have demonstrated the direct morphological control of membranes using such polymers, and systematic molecular design strategies remain underdeveloped. In this study, we report that poly(2‐propyl‐2‐oxazoline) (PPOx), a representative amphiphilic polymer, induces the formation of long string‐like structures from multilayered phospholipid films coated on silica particles. Cryo‐electron microscopy suggests that these structures are hollow lipid nanotubes, and fluorescence recovery after photobleaching (FRAP) confirmed the lateral mobility of lipids within the membranes. Furthermore, we developed an image analysis pipeline to quantitatively assess nanotube formation and evaluated the tube‐inducing efficiency of a series of poly(2‐alkyl‐2‐oxazoline) homopolymers with varying side‐chain hydrophobicities.
- Open Access
Mesenchymal Stem Cell Membrane Coating of Gelatin Nanospheres with Drug Release Ability for Inflammatory Tissue Targeting
Improvements in drug delivery have been achieved using nanospheres to prolong drug efficacy, accelerate absorption, and target tissues with ongoing inflammation. Although nanospheres have numerous pharmacokinetic advantages their tissue-targeting ability is poor. In contrast, mesenchymal stem cells (MSC) accumulate in high numbers in inflammatory tissues via the interaction between CXC-chemokine receptor 4 (CXCR4) expressed on MSC and stromal cell-derived factor 1 (SDF-1) secreted during inflammation. Therefore, this study investigated coating gelatin nanospheres (GNS) with MSC membranes (MSC-GNS) by extrusion and ultrasonication methods to enhance their inflammatory tissue tropism. ζ-potential measurements, western blotting and single-particle analysis of MSC-GNS by flow cytometry demonstrated the GNS surface was successfully coated with MSC membranes. Dot blotting demonstrated the binding ability of CXCR4 for SDF-1 was retained by MSC-GNS but absent for MSC-membrane-free GNS. The blood clearance of MSC-GNS was examined by their intravenous injection into mice. Although MSC-GNS and GNS were retained during the early distribution phase, MSC-GNS had a higher retention than GNS during the later elimination phase. Finally, we investigated the tissue distribution of MSC-GNS by intravenous injection into a mouse model of liver fibrosis and their potential therapeutic effect on liver fibrosis. We found a higher accumulation of MSC-GNS in inflamed livers and higher blood retention compared with MSC-membrane-free GNS. Furthermore, MSC-GNS loaded with an anti-fibrotic agent (LSKL, a 4-amino acid peptide that inhibits fibrosis progression) had an enhanced therapeutic effect on liver fibrosis than uncoated nanoparticles. Therefore, MSC-GNS might be a drug carrier with inflammatory tissue targeting and controlled drug release abilities. Synopsis Table of Contents GraphicMesenchymal stem cell membrane coated gelatin nanosphere as DDS nanocarrier
Open AccessMesenchymal Stem Cell Membrane Coating of Gelatin Nanospheres with Drug Release Ability for Inflammatory Tissue Targeting
Improvements in drug delivery have been achieved using nanospheres to prolong drug efficacy, accelerate absorption, and target tissues with ongoing inflammation. Although nanospheres have numerous pharmacokinetic advantages their tissue-targeting ability is poor. In contrast, mesenchymal stem cells (MSC) accumulate in high numbers in inflammatory tissues via the interaction between CXC-chemokine receptor 4 (CXCR4) expressed on MSC and stromal cell-derived factor 1 (SDF-1) secreted during inflammation. Therefore, this study investigated coating gelatin nanospheres (GNS) with MSC membranes (MSC-GNS) by extrusion and ultrasonication methods to enhance their inflammatory tissue tropism. ζ-potential measurements, western blotting and single-particle analysis of MSC-GNS by flow cytometry demonstrated the GNS surface was successfully coated with MSC membranes. Dot blotting demonstrated the binding ability of CXCR4 for SDF-1 was retained by MSC-GNS but absent for MSC-membrane-free GNS. The blood clearance of MSC-GNS was examined by their intravenous injection into mice. Although MSC-GNS and GNS were retained during the early distribution phase, MSC-GNS had a higher retention than GNS during the later elimination phase. Finally, we investigated the tissue distribution of MSC-GNS by intravenous injection into a mouse model of liver fibrosis and their potential therapeutic effect on liver fibrosis. We found a higher accumulation of MSC-GNS in inflamed livers and higher blood retention compared with MSC-membrane-free GNS. Furthermore, MSC-GNS loaded with an anti-fibrotic agent (LSKL, a 4-amino acid peptide that inhibits fibrosis progression) had an enhanced therapeutic effect on liver fibrosis than uncoated nanoparticles. Therefore, MSC-GNS might be a drug carrier with inflammatory tissue targeting and controlled drug release abilities. Synopsis Table of Contents GraphicMesenchymal stem cell membrane coated gelatin nanosphere as DDS nanocarrier
- Open Access
- 6 November 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (22) , 11942
Distribution and Incorporation of Extracellular Vesicles into Chondrocytes and Synoviocytes
Osteoarthritis (OA) is a chronic disease affecting over 500 million people worldwide. As the population ages and obesity rates rise, the societal burden of OA is increasing. Pro-inflammatory cytokines, particularly interleukin-1β, are implicated in the pathogenesis of OA. Recent studies suggest that crosstalk between cartilage and synovium contributes to OA development, but the mechanisms remain unclear. Extracellular vesicles (EVs) were purified from cell culture-conditioned medium via ultracentrifugation and confirmed using transmission electron microscopy, nanoparticle tracking analysis, and western blotting. We demonstrated that EVs were taken up by human synoviocytes and chondrocytes in vitro, while in vivo experiments revealed that fluorescent-labelled EVs injected into mouse joints were incorporated into chondrocytes and synoviocytes. EV uptake was significantly inhibited by dynamin-mediated endocytosis inhibitors, indicating that endocytosis plays a major role in this process. Additionally, co-culture experiments with HEK-293 cells expressing red fluorescent protein (RFP)-tagged CD9 and the chondrocytic cell line OUMS-27 confirmed the transfer of RFP-positive EVs across a 600-nm but not a 30-nm filter. These findings suggest that EVs from chondrocytes are released into joint fluid and taken up by cells within the cartilage, potentially facilitating communication between cartilage and synovium. The results underscore the importance of EVs in OA pathophysiology.
- 6 November 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (22) , 11942
Open AccessDistribution and Incorporation of Extracellular Vesicles into Chondrocytes and Synoviocytes
Osteoarthritis (OA) is a chronic disease affecting over 500 million people worldwide. As the population ages and obesity rates rise, the societal burden of OA is increasing. Pro-inflammatory cytokines, particularly interleukin-1β, are implicated in the pathogenesis of OA. Recent studies suggest that crosstalk between cartilage and synovium contributes to OA development, but the mechanisms remain unclear. Extracellular vesicles (EVs) were purified from cell culture-conditioned medium via ultracentrifugation and confirmed using transmission electron microscopy, nanoparticle tracking analysis, and western blotting. We demonstrated that EVs were taken up by human synoviocytes and chondrocytes in vitro, while in vivo experiments revealed that fluorescent-labelled EVs injected into mouse joints were incorporated into chondrocytes and synoviocytes. EV uptake was significantly inhibited by dynamin-mediated endocytosis inhibitors, indicating that endocytosis plays a major role in this process. Additionally, co-culture experiments with HEK-293 cells expressing red fluorescent protein (RFP)-tagged CD9 and the chondrocytic cell line OUMS-27 confirmed the transfer of RFP-positive EVs across a 600-nm but not a 30-nm filter. These findings suggest that EVs from chondrocytes are released into joint fluid and taken up by cells within the cartilage, potentially facilitating communication between cartilage and synovium. The results underscore the importance of EVs in OA pathophysiology.
- Open Access
- 25 November 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (12) , 2601
A Simple Preparation Method of Gelatin Hydrogels Incorporating Cisplatin for Sustained Release
The objective of this study was to develop a new preparation method for cisplatin (CDDP)-incorporated gelatin hydrogels without using chemical crosslinking nor a vacuum heating instrument for dehydrothermal crosslinking. By simply mixing CDDP and gelatin, CDDP-crosslinked gelatin hydrogels (CCGH) were prepared. CDDP functions as a crosslinking agent of gelatin to form the gelatin hydrogel. Simultaneously, CDDP is incorporated into the gelatin hydrogel as a controlled release carrier. CDDP’s in vitro and in vivo anticancer efficacy after incorporation into CCGH was evaluated. In the in vitro system, the CDDP was released gradually due to CCGH degradation with an initial burst release of approximately 16%. CDDP metal-coordinated with the degraded fragment of gelatin was released from CCGH with maintaining the anticancer activity. After intraperitoneal administration of CCGH, CDDP was detected in the blood circulation while its toxicity was low. Following intraperitoneal administration of CCGH in a murine peritoneal dissemination model of human gastric cancer MKN45-Luc cell line, the survival time was significantly prolonged compared with free CDDP solution. It is concluded that CCGH prepared by the CDDP-based crosslinking of gelatin is an excellent sustained release system of CDDP to achieve superior anticancer effects with minimal side effects compared with free CDDP solution.
- 25 November 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (12) , 2601
Open AccessA Simple Preparation Method of Gelatin Hydrogels Incorporating Cisplatin for Sustained Release
The objective of this study was to develop a new preparation method for cisplatin (CDDP)-incorporated gelatin hydrogels without using chemical crosslinking nor a vacuum heating instrument for dehydrothermal crosslinking. By simply mixing CDDP and gelatin, CDDP-crosslinked gelatin hydrogels (CCGH) were prepared. CDDP functions as a crosslinking agent of gelatin to form the gelatin hydrogel. Simultaneously, CDDP is incorporated into the gelatin hydrogel as a controlled release carrier. CDDP’s in vitro and in vivo anticancer efficacy after incorporation into CCGH was evaluated. In the in vitro system, the CDDP was released gradually due to CCGH degradation with an initial burst release of approximately 16%. CDDP metal-coordinated with the degraded fragment of gelatin was released from CCGH with maintaining the anticancer activity. After intraperitoneal administration of CCGH, CDDP was detected in the blood circulation while its toxicity was low. Following intraperitoneal administration of CCGH in a murine peritoneal dissemination model of human gastric cancer MKN45-Luc cell line, the survival time was significantly prolonged compared with free CDDP solution. It is concluded that CCGH prepared by the CDDP-based crosslinking of gelatin is an excellent sustained release system of CDDP to achieve superior anticancer effects with minimal side effects compared with free CDDP solution.
- Open Access
- 4 August 2020
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 10 (48) , 28741-28745
Preparation of cationic proteoliposomes using cell-free membrane protein synthesis: the chaperoning effect of cationic liposomes
The preparation method of cationic proteoliposomes is established using a cell-free membrane protein synthesis in the presence of cationic liposomes.
- 4 August 2020
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 10 (48) , 28741-28745
Open AccessPreparation of cationic proteoliposomes using cell-free membrane protein synthesis: the chaperoning effect of cationic liposomes
The preparation method of cationic proteoliposomes is established using a cell-free membrane protein synthesis in the presence of cationic liposomes.
- Open Access
- 23 August 2018
- Published by Wiley in Advanced Science
- Vol. 5 (10) , 1800524
Proteoliposome Engineering with Cell‐Free Membrane Protein Synthesis: Control of Membrane Protein Sorting into Liposomes by Chaperoning Systems
Integral membrane proteins (IMPs) modulate key cellular processes; their dysfunctions are closely related to disease. However, production of IMPs in active conformations for further study is hindered by aggregation and toxicity in living expression systems. IMPs are therefore produced in cell‐free systems employing liposome chaperoning, but membrane integration of the nascent IMPs is suboptimal and orientation of the integrated proteins remains uncontrollable. Thus, an artificial membrane protein sorting system is developed, based on polyhistidine/nickel‐chelate affinity, combined with cell‐free membrane protein synthesis. Its proof of concept is demonstrated with a N‐terminal hexahistadine‐fused conexin‐43 (NHis–Cx43) model IMP. Nickel‐chelating liposomes efficiently incorporate twofold newly synthesized NHis–Cx43 compared with Cx43. NHis–Cx43, when synthesized in this system, forms dye‐permeable hemichannels, similar to plasma membrane pores formed by Cx43 in cells. The topology of incorporated NHis–Cx43 indicates two orientations in the liposomal membranes. However, NHis–Cx43 orientation is controlled, resulting in single topology, by combination of the natural molecular chaperone DnaKJE. Successful synthesis and at least 4.5‐fold increase lipid incorporation are also achieved with three other NHis‐fused IMPs, including α‐helix and β‐barrel IMPs. Overall, this simple membrane protein sorting system is usable combined with molecular chaperones to prepare proteoliposomes for many applications.
- 23 August 2018
- Published by Wiley in Advanced Science
- Vol. 5 (10) , 1800524
Open AccessProteoliposome Engineering with Cell‐Free Membrane Protein Synthesis: Control of Membrane Protein Sorting into Liposomes by Chaperoning Systems
Integral membrane proteins (IMPs) modulate key cellular processes; their dysfunctions are closely related to disease. However, production of IMPs in active conformations for further study is hindered by aggregation and toxicity in living expression systems. IMPs are therefore produced in cell‐free systems employing liposome chaperoning, but membrane integration of the nascent IMPs is suboptimal and orientation of the integrated proteins remains uncontrollable. Thus, an artificial membrane protein sorting system is developed, based on polyhistidine/nickel‐chelate affinity, combined with cell‐free membrane protein synthesis. Its proof of concept is demonstrated with a N‐terminal hexahistadine‐fused conexin‐43 (NHis–Cx43) model IMP. Nickel‐chelating liposomes efficiently incorporate twofold newly synthesized NHis–Cx43 compared with Cx43. NHis–Cx43, when synthesized in this system, forms dye‐permeable hemichannels, similar to plasma membrane pores formed by Cx43 in cells. The topology of incorporated NHis–Cx43 indicates two orientations in the liposomal membranes. However, NHis–Cx43 orientation is controlled, resulting in single topology, by combination of the natural molecular chaperone DnaKJE. Successful synthesis and at least 4.5‐fold increase lipid incorporation are also achieved with three other NHis‐fused IMPs, including α‐helix and β‐barrel IMPs. Overall, this simple membrane protein sorting system is usable combined with molecular chaperones to prepare proteoliposomes for many applications.
- 8 December 2016
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 106 (3) , 892-897
Targeted Delivery of Interferon Gamma Using a Recombinant Fusion Protein of a Fibrin Clot–Binding Peptide With Interferon Gamma for Cancer Gene Therapy
- 8 December 2016
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 106 (3) , 892-897
Targeted Delivery of Interferon Gamma Using a Recombinant Fusion Protein of a Fibrin Clot–Binding Peptide With Interferon Gamma for Cancer Gene Therapy